Contact this trialFirst, we need to learn more about you.
Cyclin-Dependent Kinase (CDK) Inhibitor
Abemaciclib + Darolutamide for Advanced Prostate Cancer
Recruiting1 awardPhase 1
Springdale, Arkansas
This trial is exploring the safety & tolerability of combining abemaciclib & darolutamide for advanced prostate cancer treatment. Participation may last 32 months.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.